PTSM: Pharmaceutical Technology Sourcing and Management
The companies entered into a manufacturing agreement for voclosporin active pharmaceutical ingredient.
Aurinia Pharmaceuticals announced on Dec. 19, 2016 that the company has entered into a long-term agreement with Lonza for the manufacture of voclosporin API. This agreement follows a multi-year clinical manufacturing relationship where the companies have refined the process and analytical methods to produce clinical and commercial supplies of voclosporin. Under the terms of the agreement, Lonza will produce cGMP-grade voclosporin drug substance for use in Aurinia’s Phase III lupus nephritis (LN) clinical program and for future commercial use. The agreement also provides an option for Lonza to exclusively supply API for up to 20 years.
Source: Aurina Pharmaceuticals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.